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Summary
Background Helicobacter pylori infection is a major cause of non-cardia gastric cancer (NCGC), but its causal role in 
cardia gastric cancer (CGC) is unclear. Moreover, the reported magnitude of association with NCGC varies 
considerably, leading to uncertainty about population-based H pylori screening and eradication strategies in high-risk 
settings, particularly in China, where approximately half of all global gastric cancer cases occur. Our aim was to assess 
the associations of H pylori infection, both overall and for individual infection biomarkers, with the risks of NCGC 
and CGC in Chinese adults.
Methods A case-cohort study was done in adults from the prospective China Kadoorie Biobank study, aged 30–79 years 
from ten areas in China (Qingdao, Haikou, Harbin, Suzhou, Liuzhou, Henan, Sichuan, Hunan, Gansu, and Zhejiang), 
and included 500 incident NCGC cases, 437 incident CGC cases, and 500 subcohort participants who were cancer-
free and alive within the first two years since enrolment in 2004–08. H pylori biomarkers were measured in stored 
baseline plasma samples using a sensitive immunoblot assay (HelicoBlot 2.1), with adapted criteria to define H pylori 
seropositivity. Cox regression was used to estimate adjusted hazard ratios (HRs) for NCGC and CGC associated with 
H pylori infection. These values were used to estimate the number of gastric cancer cases attributable to H pylori 
infection in China.
Findings Of the 512 715 adults enrolled in the China Kadoorie Biobank between June, 2004, and July, 2008, 500 incident 
NCGC cases, 437 incident CGC cases, and 500 subcohort participants were selected for analysis. The seroprevalence 
of H pylori was 94·4% (95% CI 92·4–96·4) in NGCG, 92·2% (89·7–94·7) in CGC, and 75·6% (71·8–79·4) in 
subcohort participants. H pylori infection was associated with adjusted HRs of 5·94 (95% CI 3·25–10·86) for NCGC 
and 3·06 (1·54–6·10) for CGC. Among the seven individual infection biomarkers, cytotoxin-associated antigen had 
the highest HRs for both NCGC (HR 4·41, 95% CI 2·60–7·50) and CGC (2·94, 1·53–5·68). In this population, 
78·5% of NCGC and 62·1% of CGC cases could be attributable to H pylori infection. H pylori infection accounted for 
an estimated 339 955 cases of gastric cancer in China in 2018.
Interpretation Among Chinese adults, H pylori infection is common and is the cause of large numbers of gastric 
cancer cases. Population-based mass screening and the eradication of H pylori should be considered to reduce the 
burden of gastric cancer in high-risk settings.
Funding Cancer Research UK, Wellcome Trust, UK Medical Research Council, British Heart Foundation, Kadoorie 
Charitable Foundation, National Key Research and Development Program of China, and National Natural Science 
Foundation of China.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction 
Gastric cancer is the fifth most frequently diagnosed 
cancer and the second leading cause of cancer death 
globally, causing more than 1 million new cases and 
approximately 770 000 deaths in 2020, with China alone 
accounting for approximately half (478 000) of the number 
of global new cases.1 One of the most notable and 
preventable causes of gastric cancer is Helicobacter pylori 
infection, which caused an estimated 0·8 million new 
gastric cancer cases globally in 2018, based mainly on 
relative risk (RR) estimates from studies in populations 
from Europe, the USA, and Australia.2
The prevalence of H pylori infection varies greatly 
between and within countries, from 20% to 50% in high-
income countries to more than 80% in many low-income 
countries.3 Although several epidemiological studies 
have consistently shown the strong association of non-
cardia gastric cancer (NCGC) with H pylori infection in 
diverse populations, the reported RR estimates varied 
considerably between the studies.4–6 Moreover, there is 
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substantial uncertainty about the role of H pylori infection 
in the cause of cardia gastric cancer (CGC), which 
accounts for approximately a third of gastric cancer cases 
globally. By contrast to a few east Asian studies showing a 
positive association of CGC with H pylori infection,7,8 
albeit more modest than that for NCGC, most studies of 
populations in Europe, the USA, and Australia have 
reported either null or reduced risks of CGC associated 
with H pylori infection.5,9
As a result of chronic H pylori infection, a high 
proportion of people with gastric cancer might develop 
severe gastric atrophy several years before cancer 
development,10 which could reduce antibody concen-
trations and substantially underestimate the risk of 
H pylori infection in case-control studies or prospective 
studies with a short follow-up, in which H pylori infection 
is measured after or shortly before cancer diagnosis.5 
Moreover, the risk estimates might also be affected by 
Research in context
Evidence before this study
We searched for articles in PubMed published in English, 
Chinese, and other languages (including Japanese and Korean 
with English abstracts available, but with a focus on papers 
published in English) from Jan 1, 1990, to Dec 8, 2020, 
for individual studies or pooled or meta-analyses on 
Helicobacter pylori infection and risks of gastric cancer. 
The search terms (“H. pylori” or “Helicobacter pylori”) and 
(“gastric” or “non-cardia” or “cardia” or “stomach”) and 
(“cancer” or “carcinoma”) and (“risk” or “association”) 
were used. Overall, we identified six pooled analyses or 
meta-analyses that included approximately 20 prospective 
studies and a larger number of retrospective studies, 
with approximately a third involving east Asian populations. 
For non-cardia gastric cancer (NCGC), most studies have 
consistently shown a positive association with H pylori 
infection, but the relative risk (RR) estimates varied by more 
than 20 times, partly because of differences in study design, 
assay methods used, and exclusion criteria applied to reduce the 
effects of gastric atrophy on H pylori seropositivity. In a pooled 
analysis undertaken by the Helicobacter and Cancer 
Collaborative Group that included 12 prospective studies, 
H pylori infection as established by ELISA was associated with a 
3·0-fold (95% CI 2·3–3·8; n=762 cases) increased risk of NCGC, 
with a higher RR (5·9, 95% CI 3·4–10·3; n=223 cases) after 
restricting analyses to cases with blood samples collected over 
10 years before cancer diagnosis. More recently, in a pooled 
analysis of three nested case-control studies of populations in 
Europe, the USA, and Australia using a more sensitive 
immunoblot assay (HelicoBlot 2·1) for H pylori infection, 
the reported RR was 17·0 (11·6–25·0; n=189 cases) for NCGC, 
much higher than that obtained using ELISA in the same study 
population. Previous studies of H pylori infection and cardia 
gastric cancer (CGC), which accounts for approximately 30% of 
gastric cancer, have produced conflicting findings, especially 
between studies in east Asia and Europe, the USA, 
and Australia. In the aforementioned pooled analysis by HCCG 
(n=274 CGC cases) and a subsequent meta-analysis of 
34 studies that also included many retrospective studies, 
H pylori infection showed either a null or negative association 
with CGC in populations in Europe, the USA, and Australia, 
but a positive, albeit more modest compared with NCGC, 
association in east Asian populations. In mainland China, where 
approximately half of all global gastric cancer cases currently 
occur, only four prospective studies have examined the 
associations of H pylori infection with gastric cancer. None have 
used immunoblot assays, excluded cases diagnosed within the 
first few years after sample collection, or covered multiple 
diverse areas. Although they showed positive associations of 
H pylori infection with overall gastric cancer, or with NCGC and 
CGC if available, there was substantial uncertainty about the 
magnitude of the associations.
Added value of this study
Our study had a case-cohort design within the large prospective 
China Kadoorie Biobank of 0·5 million adults recruited from 
ten geographically diverse areas in China. In addition to the 
inclusion of many adjudicated NCGC and CGC cases that 
occurred at least 2 years after sample collection, it also used a 
sensitive immunoblot assay to detect H pylori infection. 
Our study showed that H pylori infection was associated with 
6-times higher risk of NCGC and 3-times higher risk of CGC.
These RR estimates were approximately twice those previously 
reported among Chinese adults. We further estimated that 
approximately 80% of cases of NCGC and more than 60% of 
cases of CGC currently occurring in China each year could be 
attributable to H pylori infection. In a combined analysis of the 
present study with published data from three studies in Europe, 
the USA, and Australia that used the same HelicoBlot assay, 
the pooled RR for NCGC was 8·95 (95% CI 5·59–14·33), which 
can inform the future estimation of the disease burden 
associated with H pylori infection regionally and globally.
Implications of all the available evidence
The reliable estimation of the risk and burden of gastric cancer 
due to H pylori infection will help policy makers to develop and 
implement suitable strategies for cancer prevention locally 
and globally. The new evidence from this study should help to 
refine the estimation of the global gastric cancer burden 
attributable to H pylori infection. More importantly, 
our findings, combined with evidence from a randomised 
controlled trial of the effects of H pylori treatment on gastric 
cancer risks in China, suggest that population-based H pylori 
screening and eradication should be considered as a key 
strategy for gastric cancer prevention, before considering 
mass gastric cancer screening by barium photofluorography or 
endoscopy in China and other high-risk settings.
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the sensitivity of the assay used to measure H pylori 
antibodies. In populations in Europe, the USA, and 
Australia, the immunoblot assay has proven to be more 
sensitive than conventional ELISA to detect H pylori 
antibodies, with some studies reporting 2–5 times higher 
risks for NCGC with an immunoblot than with ELISA in 
the same study populations.6,11–13 However, these previous 
studies tended to be small, typically involving fewer than 
100 patients with cancer. To our knowledge, no large 
prospective study using an immunoblot assay has been 
done in China where H pylori infection is highly prevalent, 
with different H pylori strain-specific features from 
populations in Europe, the USA, and Australia.14
Using an immunoblot assay and a case-cohort study 
design within the prospective China Kadoorie Biobank 
study of more than 0·5 million adults from ten geo- 
graphically diverse areas, we aimed to assess the 
associations of H pylori infection, both overall and for 
individual infection biomarkers, with risks of NCGC and 
CGC in Chinese adults. We also estimated the number of 




Details of the design, methods, and study participants in 
the China Kadoorie Biobank study have been previously 
described.15 Briefly, the baseline survey was done 
between June, 2004, and July, 2008, in ten (five urban and 
five rural) geo graphically diverse areas across China 
(Qingdao, Haikou, Harbin, Suzhou, Liuzhou, Henan, 
Sichuan, Hunan, Gansu, and Zhejiang) and enrolled 
512 715 adults aged 30–79 years. The ten regions were 
selected with the aim to maximise the diversity from the 
geographical locations, socioeconomic characteristics, 
risk exposures, and disease patterns, while considering 
the quality of death and disease registries and local 
capacity. In each study area, a regional coordinating 
centre and survey team were set up and all permanent 
residents aged 30–79 years identified from local 
residential records were invited to participate. Extensive 
data were collected through a laptop-based questionnaire 
(eg, socio demo graphic, lifestyle and dietary factors, and 
medical history) and physical measurements (eg, blood 
pressure and adiposity), along with the collection of a 
10 mL blood sample for long-term storage. Ethics 
approval was obtained from relevant international, 
national, and local ethics committees (in the UK, Oxford 
Tropical Research Ethics Committee; in China, the 
Chinese Centre for Disease Control and Prevention 
Ethical Review Committee and the Chinese Academy of 
Medical Sciences and Peking Union Medical College 
Ethical Committee). All participants provided written 
informed consent.
Follow-up of participants in the China Kadoorie 
Biobank study was done through linkage, via unique 
personal identification numbers, to established mor tality 
and morbidity registries (for cancer, stroke, ischaemic 
heart disease, and diabetes) that were already available in 
the study areas since the beginning of the baseline 
survey, and to the nationwide health insurance system, 
which records any episodes of patients being admitted to 
and staying in hospital as inpatients. By Jan 1, 2017, 
44 037 (8·6%) participants had died, 4781 (<1%) were lost 
to follow-up, and 27 903 (5·4%) developed cancer, 
including 3464 gastric cancers (International Classification 
of Disease 10 [ICD-10]: C16). For any reported cancer 
cases, systematic validation was done through a review of 
the original medical records (including histopathological 
reports) retrieved from hospitals. Among the 1355 rep -
orted gastric cancer cases that were adjudicated, 
1246 (92%) were confirmed, and among the confirmed 
cases with pathology results available, 1060 (85%) of 
1246 were adenocarcinomas.
Design of case-cohort study 
To reduce the potential effects of lower H pylori antibody 
concentrations due to gastric atrophy, the selection 
of incident gastric cancer cases were confined to 
participants who were alive and with no history of cancer 
2 years after study entry. All 437 reported or confirmed 
CGC cases (ICD-10: C16·0) were selected, and we 
randomly selected 500 cases from the 762 confirmed 
NCGC (of 2035 reported) cases. Since CGC arises in the 
oesophageal-gastric junction and is often difficult to 
distinguish from oesophageal adenocarcinoma, which is 
rare in China, we also included all confirmed oe-
sophageal adenocarcinoma cases (n=27). A subcohort of 
500 participants was sampled from the modified baseline 
cohort (ie, participants who were alive with no history of 
cancer 2 years after study entry) using stratified random 
sampling with the sizes of the strata based on the 
proportions of age categories and sex of all selected 
participants with gastric cancer (appendix p 2). This 
modified baseline subcohort included approximately 
100 000 previously genotyped participants who were 
randomly selected from the whole cohort.
Immunoblot assay 
A qualitative western blot kit assay, HelicoBlot 2.1 
(MP Diagnostics; Bordeaux, France), was used to detect 
IgG antibodies to H pylori proteins in the baseline plasma 
samples retrieved from storage in liquid nitrogen. The 
assay detects seven diagnostic antibodies binding to 
H pylori proteins separated on a nitrocellulose membrane 
and has been shown to have a sensitivity of 96% and a 
specificity of 93% for the detection of H pylori infections 
in populations in Europe.16 The immunoblot assay results 
were independently classified and reviewed by 
two laboratory staff (one of which was DC) who were 
masked to the baseline information and case status of the 
samples. Each H pylori biomarker band was classified as 
positive, negative, or ambiguous. These results were then 
used to define H pylori seropositivity according to 
See Online for appendix
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two different criteria. The clinical criteria, as defined 
by the manufacturer of the western blot kit, were the 
presence of one or more of the 89kD (vacuolating 
cytotoxin), 37kD, or 35kD bands; or both the 30kD (urease 
enzyme light subunit) and 19·5kD bands; or both the 
116kD (cytotoxin-associated antigen) and the current 
infection marker bands. For this study, we modified the 
criteria by removing the requirement to have the current 
infection marker band alongside the cytotoxin-associated 
antigen band (ie, the cytotoxin-associated antigen band 
alone can define seropositivity). This choice was made for 
two reasons: first, the current infection marker band is 
more likely to be absent in patients with atrophic stomach 
or precancerous lesions; and second, the presence of 
antibodies to cytotoxin-associated antigen is the most 
sensitive marker of a past infection,17 which makes it 
relevant for investigating the role of H pylori infection in 
patients progressing towards cancer. These modified 
criteria are thereafter referred to as epidemiological 
criteria (appendix p 3).
Statistical analysis 
Seroprevalence estimates and their 95% CIs were 
calculated among the NCGC, CGC, and subcohort 
groups. Spearman's correlations between H pylori 
biomarkers were calculated. Cox proportional hazards 
models were fitted using the pseudo-partial likelihood 
for the Borgan III estimator18 to estimate hazard 
ratios (HRs) for risk of NCGC, CGC, and oesophageal 
adenocarcinoma associated with H pylori infection, both 
overall and by individual H pylori biomarkers, with 
adjustments for age (numeric), sex, individual study 
regions, and education (six categories: no formal school, 
primary school, middle school, high school, technical 
school or college, and university). Time in the study 
(time from 2 years after entry into the study to cancer 
diagnosis, loss to follow-up, death because of other 
causes, or Jan 1, 2017, whichever occurred first) was 
used as the timescale in the model. Models were also 
fitted additionally and sequentially adjusting for other 
gastric cancer risk factors, including smoking, alcohol 
drinking, a family history of cancer, body-mass index, 
and the consumption of some dietary factors 
(eg, preserved vegetables or fresh fruits). We fitted Cox 
regression models with piecewise constant time-varying 
coefficients using the Prentice estimator, with strati-
fication by the design stratification variables (age groups 
and sex) and adjustment for age (years), individual 
study regions, and education. We addi tionally assessed 
the proportional hazards assumption using Schoenfeld 
residuals.
We did sensitivity analyses by assuming that all 
ambiguous bands were either seropositive or sero-
negative. Further analyses were done in subgroups 
defined by age (30–59 and 60–79 years), sex, area (rural or 
urban), education (two groups: no formal education or 
primary school, and middle school or higher), and body-
mass index (<25 or ≥25 kg/m²); and among men only, by 
regular smoking and alcohol drinking. HRs were also 
calculated for different gastric cancer histopathological 
subtypes and by the time since blood collection 
(individuals with ambiguous H pylori status were 
NCGC (n=499) CGC (n=436) Subcohort (n=500)
Demographic factors
Age (years) 59·0 (9·5) 61·2 (8·6) 59·1 (9·9)
Sex
Men 327 (66%) 325 (75%) 347 (69%)
Women 172 (34%) 111 (25%) 153 (31%)
Urban residents 351 (70%) 159 (36%) 252 (50%)
≥6 years of education 225 (45%) 141 (32%) 217 (43%)
Household income (>¥20 000 per year) 231 (46%) 132 (30%) 210 (42%)
Lifestyle factors
Current regular smoking
Men 230 (70%) 186 (57%) 202 (58%)
Women 5 (3%) 0 6 (4%)
Current regular alcohol drinking
Men 134 (41%) 89 (27%) 111 (32%)
Women 2 (1%) 0 7 (5%)
Physical activity (MET-h per day) 19·5 (15·2) 18·1 (15·5) 17·9 (14·0)
Medical history and health status
Poor self-rated health at baseline 46 (9%) 53 (12%) 55 (11%)
Diabetes (self-reported or screen 
detected)
32 (6%) 25 (6%) 44 (9%)
A history of peptic ulcer 31 (6%) 23 (5%) 27 (5%)
A history of cirrhosis or chronic 
hepatitis
3 (1%) 3 (1%) 6 (1%)
A history of CHD, stroke, or TIA 28 (6%) 31 (7%) 52 (10%)
A history of emphysema or bronchitis 12 (2%) 18 (4%) 21 (4%)
Anthropometry and blood pressure
Body mass index (kg/m2) 23·6 (3·4) 24·0 (3·5) 23·7 (3·5)
Underweight (<18·5 kg/m2) 25 (5%) 14 (3%) 26 (5%)
Normal (18·5–24·9 kg/m2) 314 (63%) 266 (61%) 301 (60%)
Overweight (25·0–29·9 kg/m2) 136 (27%) 135 (31%) 150 (30%)
Obese (≥30 kg/m2) 24 (5%) 21 (5%) 23 (5%)
Waist circumference (cm) 81·1 (10·1) 82·3 (10·2) 81·4 (10·3)
SBP (mm Hg) 135·3 (22·8) 138·0 (23·1) 135·8 (22·5)
Daily dietary consumption
Rice 337 (68%) 183 (42%) 358 (72%)
Wheat 221 (44%) 271 (62%) 188 (38%)
Meat 174 (35%) 69 (16%) 150 (30%)
Poultry 6 (1%) 0 2 (0%)
Dairy 86 (17%) 41 (9.4) 64 (12.8)
Fresh vegetables 474 (95%) 424 (97%) 481 (96%)
Soybean 24 (5%) 14 (3%) 18 (4%)
Preserved vegetables 160 (32%) 105 (24%) 86 (17%)
Fresh fruit 125 (25%) 32 (7%) 97 (19%)
Spicy food 86 (17%) 41 (9%) 122 (24%)
Data are mean (SD) or number (%). CGC=cardia gastric cancer. CHD=coronary heart disease. MET-h=metabolic 
equivalent of task-hours. NCGC=non-cardia gastric cancer. SBP=systolic blood pressure. TIA=transient ischaemic attack.
Table 1: Baseline characteristics of patients with gastric cancer (NCGC and CGC) and subcohort 
participants
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excluded from this analysis). To facilitate comparisons 
with previous studies, additional sensitivity analyses 
were done using the clinical criteria to define H pylori 
seropositivity.
Population attributable fractions (PAFs) were calculated 
as PAF=Pc (R–1) / R, where Pc is the observed 
seroprevalence among the cases and R is the estimated 
HR associated with H pylori infection in the study.2 The 
number of new gastric cancer cases attri butable to 
H pylori infection was estimated by multiplying the PAF 
by the national incidence rates of gastric cancer in 
China in 2018.19 Statistical analysis was done with R 
(version 4.0.2).
Role of the funding source 
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results 
After a median 10·1 years (IQR 9·2–11·1) of follow-up, 
the incidence in the whole cohort was 57·6 per 
100 000 person-years for NCGC and 10·5 per 
100 000 person-years for CGC, both of which increased 
with age. In each age group, men had a nearly 3 times 
higher rate than did women (appendix p 4). One case of 
CGC and one case of NCGC had missing H pylori data 
and were not included in analyses.
Compared with the subcohort participants, par-
ticipants with NCGC were more likely to be urban 
residents; to have a higher socioeconomic status 
(measured by both education and household income); 
to consume meat, dairy products, and fresh fruits; to be 
regular smokers or alcohol drinkers (among men); and 
to report good self-reported health at baseline (table 1). 
For participants with CGC, however, the converse 
appeared to be true, except for preserved vegetables and 
spicy food, for which both cancer groups showed 
similar patterns to each other compared with subcohort 
participants (table 1). Because of the higher retrieval 
rates of medical notes in urban than in rural hospitals, 
disproportionally more participants with NCGC were 
selected from urban areas, which is reflected in the 
slightly better socioeconomic and health status among 
the selected participants with NCGC compared with 
those not selected for the study (appendix p 5).
Overall, the seroprevalence of H pylori infection 
was 94·4% (95% CI 92·4–96·4) in participants with 
NCGC, 92·2% (89·7–94·7) in participants with CGC, 
and 75·6% (71·8–79·4) in subcohort participants, with a 
further 12 (2·4%) of those with NCGC, 7 (1·6%) of those 
with CGC, and 21 (4·2%) in the subcohort participants 
classified as seroambiguous (appendix p 6). In the 
subcohort, the seroprevalence of H pylori infection was 
higher among urban or highly educated participants, but 
did not vary substantially by age or sex (appendix p 7). 
Among the seven biomarkers measured, cytotoxin-
associated antigen had the highest seroprevalence in 
each study group (465 [93·2%, 95% CI 91·0–95·4] 
for NCGC, 400 [91·7%, 89·2–94·3] for CGC, and 
370 [74·1%, 70·3–78·0] for the subcohort; appendix p 6). 
Moderate correlations between different H pylori 
biomarkers were observed (eg, r=0·58 between cytotoxin-
associated antigen and vacuolating cytotoxin, and r=0·48 
between cytotoxin-associated antigen and urease enzyme 
light subunit; appendix p 8).
Compared with H pylori seronegative participants, those 
who were seropositive had adjusted HRs of 5·94 (95% CI 
3·25–10·86) for NCGC and 3·06 (1·54–6·10) for CGC 
(figure 1). Additional adjustments for other risk factors did 
not materially alter the risk estimates (appendix p 9). The 
HRs did not differ significantly between women and men 
for both NCGC (16·96 vs 4·25) and CGC (7·16 vs 2·55) or 
between younger and older age groups (appendix p 10). 
Furthermore, the HRs did not differ significantly in 
population subgroups defined by other factors such as 
area, education, smoking, alcohol drinking, body-mass 
index, and family history of cancer (appendix p 10).
Figure 1: Associations of Helicobacter pylori infection, overall and by individual biomarkers, with risks of non-cardia gastric cancer and cardia gastric cancer
H pylori infection was established using epidemiological criteria. Cox regression, with the time in the study as the timescale fitted using the Borgan III estimator, 
was used to estimate HRs, with adjustment for age, sex, area, and education. The black squares represent the adjusted HRs, with the area inversely proportional to the 
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In sensitivity analyses using the clinical criteria to define 
H pylori infection, the seroprevalence in the NCGC group 
was 418 (84%) of 499, in the CGC group, 347 (80%) of 436, 
and in the subcohort, 288 (58%) of 500, with adjusted HRs 
of 4·68 (95% CI 3·13–6·98) for NCGC and 2·36 
(1·42–3·94) for CGC (appendix p 11).
Among the seven individual biomarkers, cytotoxin-
associated antigen showed the strongest association with 
the risks of NCGC and CGC, with HRs of 4·41 (95% CI 
2·60–7·50) for NCGC and 2·94 (1·53–5·68) for CGC 
(figure 1). The other biomarkers were each associated 
with an approximately 2 times increased risk of both 
cancers, except for a null association of the 35·0 kD band 
with CGC risk (figure 1). For both NCGC and CGC there 
were also indications of positive dose–response asso-
ciations with the number of positive H pylori biomarkers. 
Compared with individuals who were seronegative for all 
relevant biomarkers, individuals who were seropositive 
for both cytotoxin-associated antigen and vacuolating 
cytotoxin had HRs of 6·29 (95% CI 3·56–11·12) for 
NCGC and 3·23 (1·59–6·56) for CGC, whereas for those 
who were seropositive for both cytotoxin-associated 
antigen and urease enzyme light subunit, the HRs were 
5·01 (2·70–9·29) for NCGC and 2·54 (1·20–5·39) for 
CGC. Being seropositive for cytotoxin-associated antigen, 
vacuolating cytotoxin, and urease enzyme light subunit 
did not further increase the risk estimates (appendix p 12).
For oesophageal adenocarcinoma, although the 
adjusted HRs for overall or individual biomarkers 
sero positivity were generally similar to those for CGC, 
the 95% CIs were wide because of the small number of 
cases involved (appendix p 13).
Although no statistically significant time interaction 
was detected, for both NCGC and CGC the HRs at 
3–4 years were approximately half of those at 5–6 or 
7 years or more since sample collection (table 2). The 
associations did not differ significantly between major 
histopathological subtypes of cancer (appendix p 14).
Compared with seronegative participants, those with 
ambiguous H pylori infection status had adjusted HRs 
of 4·08 (95% CI 1·56–10·66) for NCGC and of 0·99 
(95% CI 0·23–4·21) for CGC. When classifying all 
ambiguous results as seropositive or seronegative, the 
HRs were attenuated for both NCGC and CGC 
(appendix p 15).
In this population, we estimated that the PAF for 
H pylori was 78·5% for NCGC and 62·1% for CGC. We 
estimated that based on the 2018 China cancer statistics,19 
H pylori infection would have caused approximately 
339 955 new cases of gastric cancer (271 389 NCGC cases 
and 68 566 CGC cases) in China annually (table 3).
Discussion 
This large prospective case-cohort study shows clearly 
that H pylori infection was a strong risk factor not only 
for NCGC but also for CGC in Chinese adults. Using a 
sensitive immunoblot assay together with the exclusion 
of the first 2 years after sample collection, we showed 
that H pylori infection was associated with a 6 times 
higher risk of NCGC and a 3 times higher risk of CGC. It 
is likely that the observed associations are largely causal, 
hence H pylori infection would have caused approximately 
80% of NCGC and more than 60% of CGC in this 
population.
Previous studies of H pylori infection and gastric cancer 
were mainly based on the less sensitive ELISA5,7,9,20 or, 
more recently, multiplex serology assays.21–24 Although an 
increased risk of NCGC with H pylori has been shown 
consistently, the magnitude of the association varied 
greatly between studies, and was generally smaller in 
Chinese populations than in populations in Europe, the 
USA, and Australia. In a pooled analysis of 12 prospective 
studies,5 H pylori infection established by ELISA was 
associated with an odds ratio (OR) of 3·0 (95% CI 
2·3–3·8) for NCGC (n=762 cases), increasing to 
5·9 (3·4–10·3) among individuals with blood samples 
collected more than 10 years before cancer diagnosis 
(n=223 cases). There is evidence from studies in Europe 
and Australia that the use of immunoblot assay leads to 
greater risk estimates than those based on ELISA. In the 
Eurogast-EPIC study involving 88 NCGC cases and 
338 controls,11 the OR for NCGC was 21·4 (95% CI 
7·1–64·4) using similar seropositivity criteria to those in 
the present study, which was three times as high as that 
based on ELISA (6·8 [95% CI 3·0–15·1]). Similar but less 
striking differences were also shown in another two small 
Number of cases HR (95% CI)*
NCGC
3–4 years 123 3·12 (1·38–7·07)
5–6 years 156 7·55 (2·66–21·45)
≥7 years 208 8·05 (3·12–20·75)
CGC
3–4 years 97 1·78 (0·74–4·26)
5–6 years 109 5·11 (1·59–16·35)
≥7 years 223 3·24 (1·52–6·87)
CGC=cardia gastric cancer. HR=hazard ratio. NCGC=non-cardia gastric cancer. 
*HRs estimated using Cox regression fitted using the Prentice estimator, 
with stratification by the design stratification variables (age groups and sex) and 
adjustment for age (years), area, and education.
Table 2: Adjusted HRs for NCGC and CGC associated with Helicobacter 
pylori infection stratified by time since blood sample collection
Seropositive (%, 
95% CI)
HR (95% CI)* Population attributable 
fractions (%)
Attributable cases
NCGC 471/499 (94·4%, 
92·4–96·4%)
5·94 (3·25–10·86) 78·5% 271 389
CGC 402/436 (92·2%, 
89·7–94·7%)
3·06 (1·54–6·10) 62·1% 68 566
CGC=cardia gastric cancer. HR=hazard ratio. NCGC=non-cardia gastric cancer. *HRs estimated using the Borgan III 
estimator and adjusted for age (years), sex, individual study regions, and education.
Table 3: The estimated numbers of cases attributable to Helicobacter pylori in China 
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studies comparing immunoblot assays with ELISA 
assays in the same study populations.12,13 Overall, these 
three studies in Europe and Australia based on 
immunoblot assays with a total of just 189 participants 
with NCGC yielded a pooled RR of 17·0 (95% CI 
11·6–25·0),6 which has been used to estimate the global 
burden of NCGC attributable to H pylori infection.2 For 
comparison, in our study using the same immunoblot 
assay and with more than 2·5 times as many participants 
as in all the three studies combined, the RR estimate for 
NCGC was only approximately a third of those of the 
previous studies. The reasons for such a large difference 
in the risk estimates are not fully understood, but might 
reflect the differences in the background prevalence of 
H pylori infection in China (75% in the China Kadoorie 
Biobank study vs 59% in Eurogast-EPIC11), and potentially 
a comparatively more notable role of other factors in the 
cause of gastric cancer in Chinese populations than other 
populations. Although not significant, we observed 
higher HRs in women, who rarely smoked or drank 
alcohol, than in men. In a combined analysis of the 
present study and the published data from these 
three studies in Europe and Australia,6 the pooled RR 
was 8·95 (5·59–14·33; figure 2), and there was no 
significant heterogeneity in the risk estimates from these 
four different studies. This updated risk estimate for 
NCGC should help inform the future estimation of the 
disease burden associated with H pylori infection, both 
regionally and globally.
The existing evidence linking CGC with H pylori 
infection remains conflicting, with studies from Europe, 
the USA, and Australia generally reporting null or inverse 
associations, whereas studies from east Asian countries 
tended to show modest positive associations. CGC is 
defined as a lesion with its centre located within 1 cm 
proximal and 2 cm distal to the oesophageal-gastric 
junction. However, there might be differences in the 
anatomical locations of CGC lesions between different 
populations, with CGC in populations in Europe, the 
USA, and Australia mainly involving the distal 
oesophagus, and in east Asians, mainly involving the 
proximal stomach.7,9 In the aforementioned pooled 
analyses of 12 prospective studies (eight in Europe, the 
USA, and Australia and four in east Asian countries), 
overall there was no clear association of H pylori infection 
with CGC (274 cases; OR 0·99 [95% CI 0·72–1·35]), with 
one study in China (n=99) showing a significant 
77% excess risk.5 In another meta-analysis of 30 studies 
(ten prospective and 20 retrospective),9 there was a 
significantly lower risk of CGC (OR 0·78, 95% CI 
0·63–0·97) in 16 studies in Europe, the USA, and 
Australia but a significantly higher risk of CGC with 
H pylori infection (RR 1·98, 95% CI 1·38–2·83) in 14 east 
Asian studies, driven mainly by large RRs in retrospective 
studies. The present study provides important new 
evidence about the role of H pylori infection in the cause 
of CGC in the Chinese population. Our RR estimates are 
approximately twice those in previous studies of Chinese 
and other Asian populations that used less sensitive 
assays and sub optimal study designs.4,7,21–24 Our findings 
are also consistent with the notion that in east Asians, 
CGC might mainly involve the proximal stomach.7,9 
Moreover, the associations were similar when the 
analyses were further confined to clinically adjudicated 
CGC cases (appendix p 16). Furthermore, the association 
of H pylori with oesophageal adenocarcinoma, which is 
rare in the Chinese population, was similar to the 
association with CGC. Further studies are warranted to 
further substantiate (or refute) the seemingly discrepant 
role of H pylori in the cause of CGC between populations 
in east Asia and in Europe, the USA, and Australia.
There is evidence that the development of atrophic 
gastritis occurs in late stage pre-malignant cases and not 
accounting for this occurrence might result in an 
underestimation of the risk associated with H pylori 
infection.25,26 Indeed, our study showed that although there 
was no evidence that the proportional hazards assumption 
is inconsistent with the data, the RRs of both NCGC and 
CGC during the early period of follow-up (even after 
excluding the first 2 years of follow-up as part of our study 
design) tended to be lower than those during the 
subsequent years of follow-up. This result suggests that 
the exclusion of the first 2 years of follow-up might have 
not fully accounted for this occurrence. If this assumption 
Figure 2: Meta-analysis of the association of Helicobacter pylori with non-cardia gastric cancer in the China Kadoorie Biobank study and three published 
studies using the same immunoblot assay
The combined estimate is an inverse-variance weighted average. The black squares represent RR, with the area inversely proportional to the variance of the log RR, 
and the horizontal lines represent their corresponding 95% CIs. The dotted vertical line indicates the overall RR, and the black diamond indicates it and its 95% CI. 
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were true, the real risk estimates (and the attributable 
fractions) for both NCGC and CGC associated with 
H pylori infection would be higher (appendix p 17).
A few studies have also shown the predominant role of 
cytotoxin-associated antigen-positive H pylori strains, in 
which nearly all participants with NCGC were cytotoxin-
associated antigen-positive.11,12 Among all H pylori bio-
markers, antibodies to cytotoxin-associated antigen have 
the strongest immunoreactivity and are the last to 
disappear after H pylori eradication or in the precancerous 
stomach.25 As such, the epidemiological criteria used in 
the present study (and the Eurogast-EPIC study11) should 
provide a good indicator of past infection. Consistent 
with previous studies of populations in Europe, the USA, 
and Australia,4,13,23,27,28 our study showed that cytotoxin-
associated antigen had the strongest associations with 
the risks of both NCGC and CGC of all the measured 
biomarkers among Chinese adults. Moreover, there were 
also higher RRs associated with larger numbers of other 
specific biomarkers (eg, vacuolating cytotoxin and urease 
enzyme light subunit) in addition to cytotoxin-associated 
antigen.
Apart from the prospective study design and inclusion 
of the large number of well characterised cases, the key 
strengths of our study were the use of a sensitive 
immunoblot assay, the exclusion of the first few years of 
follow-up to reduce the possible effects of atrophic 
gastritis on seropositivity, the ability to adjust for many 
known or potential risk factors for gastric cancer, and for 
individual study regions to account for large regional 
variations in H pylori sero prevalence and cancer rates.16 
Furthermore, our study was the first to show separate 
results from seroambiguous bands; misclassification of 
those as seropositive or seronegative is likely to bias the 
risk estimates. However, the study also has limitations. 
First, H pylori has approximately 1500 proteins,10 and the 
HelicoBlot 2.1 assay only covers seven of them. Hence, 
the effects of other H pylori proteins and their interactions 
could not be investigated. Moreover, the immunoblot 
assay used was developed on the basis of the H pylori 
strains typically seen in populations in Europe, the USA, 
and Australia, with no available data for separate 
validation nor direct com parison with conventional 
ELISA assays in Chinese populations. Second, because 
of the high retrieval rates of medical notes in urban 
hospitals, more participants with NCGC in urban areas 
were selected in our study. However, with comprehensive 
adjustment for con founding, this difference is unlikely 
to affect the RR estimates. For participants with CGC, 
given the low proportion of adjudicated cases, we also 
included reported cases, all of which were specifically 
ICD-10 coded as C16·0 when first reported, thus 
minimising the risk of misclassification. Third, we did 
not investigate simultaneously the role of other 
pathogens (eg, Epstein-Barr virus) and their potential 
interactions with H pylori in the causation of gastric 
cancer. Lastly, although various measures were taken in 
analyses, residual confounding and other unknown 
biases might persist.
In summary, the present study provides robust new 
evidence about the causal role of H pylori infection in 
both NCGC and CGC in China, where H pylori infection 
is widespread. The observed associations are probably 
largely causal and suggest that H pylori infection causes 
approximately 0·34 million gastric cancer cases annually 
in China. In addition to improving the estimation of the 
global burden of cancer because of H pylori infection, our 
study findings should also inform prevention strategies 
in China and elsewhere. To date, there is no prophylactic 
or therapeutic vaccination against H pylori. Moreover, 
despite the availability of highly cost-effective anti-H pylori 
treatments, population-based screening and eradication 
have not yet been included in the national cancer primary 
prevention programme in China. Our findings, together 
with evidence from a randomised controlled trial of 
reduced gastric cancer risk after H pylori eradication,29 
suggest that population-based H pylori mass screening 
and eradication should be considered as a key strategy 
for gastric cancer prevention, before considering mass 
gastric cancer screening by barium photofluorography or 
endoscopy in China and high-risk settings globally.
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